Sowers J R, Hershman J M, Skowsky W R, Carlson H E
Horm Res. 1976;7(4-5):232-7. doi: 10.1159/000178733.
To test the effect of thyrotropin-releasing hormone (TRH) on serum arginine vasopressin (AVP) in euthyroid and hypothyroid individuals, 500 mug of TRH was administered to four euthyroid subjects and three patients with primary hypothyroidism. Serum AVP was significantly depressed below basal levels from 30 to 60 min in the euthyroid and hypothyroid subjects after administering the releasing agent. The basal serum AVP in the hypothyroid subjects (3.1 +/- 1.1 muU/ml) was not significantly greater than the basal serum AVP in the euthyroid subjects (2.8 +/- 1.2 muU/ml). The maximal incremental depression in serum AVP after TRH in the hypothyroid subjects (1.4 +/- 0.7 muU/ml) was similar to the depression observed in the euthyroid subjects (1.8 +/- 0.9 muU/ml). These data suggest that TRH may have a physiologic role in modulation of AVP release in man.
为了测试促甲状腺激素释放激素(TRH)对甲状腺功能正常和甲状腺功能减退个体血清精氨酸加压素(AVP)的影响,对4名甲状腺功能正常的受试者和3名原发性甲状腺功能减退患者给予了500微克TRH。在给予释放剂后,甲状腺功能正常和甲状腺功能减退的受试者血清AVP在30至60分钟内显著低于基础水平。甲状腺功能减退受试者的基础血清AVP(3.1±1.1微单位/毫升)并不显著高于甲状腺功能正常受试者的基础血清AVP(2.8±1.2微单位/毫升)。甲状腺功能减退受试者在TRH后血清AVP的最大增量降低(1.4±0.7微单位/毫升)与甲状腺功能正常受试者中观察到的降低(1.8±0.9微单位/毫升)相似。这些数据表明,TRH可能在调节人类AVP释放中具有生理作用。